Chemistry:Ertumaxomab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Trifunctional antibody |
| Source | Rat/Mouse hybrid |
| Target | HER2/neu, CD3 |
| Clinical data | |
| Trade names | Rexomun |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.
It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[1]
Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[2] (So they could concentrate on their other product catumaxomab (trade name Removab).[3]:35)
References
- ↑ Fresenius
- ↑ ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
- ↑ "2009 Consolidated Financial Statements and Management Report of Fresenius SE". https://www.fresenius.com/media/gb_englisch_IFRS_2009.pdf.
 |  |
